Leukemia  >>  Phase 1
Welcome,         Profile    Billing    Logout  

406 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
NCT05823571: Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients

Recruiting
1
32
US
Itacitinib
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Incyte Corporation
Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia, CML, Myeloproliferative Disorders, Multiple Myeloma, Plasma Cell Leukemia
03/28
03/30
NCT06071624: Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.

Recruiting
1
30
US
CD4CAR
Huda Salman, iCell Gene Therapeutics, The Leukemia and Lymphoma Society
Chronic Myelomonocytic Leukemia
12/28
12/43
NCT06014762: P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies

Recruiting
1
100
US
P-CD19CD20-ALLO1, Rimiducid
Poseida Therapeutics, Inc., Roche-Genentech
Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Chronic Lymphocytic Leukemia
03/29
03/41
NCT06068868: Study to Evaluate Adverse Events and Movement of Intravenously (IV) Infused ABBV-787 in Adult Participants With Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)

Recruiting
1
60
Japan, US, RoW
ABBV-787
AbbVie
Acute Myeloid Leukemia
10/29
10/29
NCT03904069: Study Evaluating the Safety, Tolerability, and Efficacy of FLT3 CAR-T AMG 553 in FLT3-positive Relapsed/Refractory AML

Withdrawn
1
40
US
AMG 553
Amgen
Relapsed/Refractory Acute Myeloid Leukemia
08/30
08/30
NCT05507827: Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Recruiting
1
18
US
Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR), Treg CD34+HSPC (Orca-T)
Dr. Melody Smith, MD, MS, Orca Biosystems, Inc.
Lymphoid Leukemia
01/37
01/37
 

Download Options